134 related articles for article (PubMed ID: 38048788)
1. Improving survival from metastatic, recurrent, or persistent cervical cancer.
Mileshkin LR; Manoharan S
Lancet; 2024 Jan; 403(10421):2-4. PubMed ID: 38048788
[No Abstract] [Full Text] [Related]
2. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
Grau JF; Farinas-Madrid L; Oaknin A
Int J Gynecol Cancer; 2020 Jan; 30(1):139-143. PubMed ID: 31645423
[TBL] [Abstract][Full Text] [Related]
3. [Progress on clinical application of bevacizumab for the treatment of refractory cervical cancer].
He B; Chai Y; Wang T; Zhou Z; Liu Z
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2016 May; 45(4):395-402. PubMed ID: 27868413
[TBL] [Abstract][Full Text] [Related]
4. Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.
Rosen VM; Guerra I; McCormack M; Nogueira-Rodrigues A; Sasse A; Munk VC; Shang A
Int J Gynecol Cancer; 2017 Jul; 27(6):1237-1246. PubMed ID: 28448304
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer.
McNamara B; Chang Y; Mutlu L; Harold J; Santin AD
Expert Opin Biol Ther; 2023 Mar; 23(3):227-233. PubMed ID: 36800548
[TBL] [Abstract][Full Text] [Related]
6. Improved survival with bevacizumab in advanced cervical cancer.
Tewari KS; Sill MW; Long HJ; Penson RT; Huang H; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Michael HE; Monk BJ
N Engl J Med; 2014 Feb; 370(8):734-43. PubMed ID: 24552320
[TBL] [Abstract][Full Text] [Related]
7. Triplet chemotherapy vs doublet chemotherapy plus bevacizumab in metastatic, recurrent, and persistent cervical cancer.
Choi HJ; Lee YY; Choi CH; Kim TJ; Lee JW; Bae JH; Bae DS; Kim BG
Curr Probl Cancer; 2020 Oct; 44(5):100557. PubMed ID: 32067746
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Primary analysis.
Ishikawa M; Shibata T; Iwata T; Nishio S; Takada T; Suzuki S; Horie K; Kudaka W; Kagabu M; Tanikawa M; Kitagawa R; Takekuma M; Kobayashi H; Yaegashi N;
Gynecol Oncol; 2021 Aug; 162(2):292-298. PubMed ID: 34016453
[TBL] [Abstract][Full Text] [Related]
9. [Not Available].
Kurtz JE; D'Hondt V; Lécuru F; Lhommé C
Bull Cancer; 2017 May; 104 Suppl 1():S39-S42. PubMed ID: 28625314
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study.
Frumovitz M; Chisholm GB; Jhingran A; Ramalingam P; Flores-Legarreta A; Bhosale P; Gonzales NR; Hillman RT; Salvo G
Am J Obstet Gynecol; 2023 Apr; 228(4):445.e1-445.e8. PubMed ID: 36516952
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab Efficacy and Recurrence Pattern of Persistent and Metastatic Cervical Cancer.
Lee N; Kim SI; Lee M; Kim HS; Kim JW; Park NH; Song YS
In Vivo; 2019; 33(3):863-868. PubMed ID: 31028209
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients.
Godoy-Ortiz A; Plata Y; Alcaide J; Galeote A; Pajares B; Saez E; Alba E; Sánchez-Muñoz A
Clin Transl Oncol; 2018 Jul; 20(7):922-927. PubMed ID: 29222647
[TBL] [Abstract][Full Text] [Related]
13. Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer.
Redondo A; Colombo N; McCormack M; Dreosti L; Nogueira-Rodrigues A; Scambia G; Lorusso D; Joly F; Schenker M; Ruff P; Estevez-Diz M; Irahara N; Donica M; Gonzalez-Martín A
Gynecol Oncol; 2020 Oct; 159(1):142-149. PubMed ID: 32763109
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab in Metastatic, Recurrent, or Persistent Cervical Cancer: The BC Cancer Experience.
Tinker AV; Fiorino L; O'Dwyer H; Kumar A
Int J Gynecol Cancer; 2018 Oct; 28(8):1592-1599. PubMed ID: 30247250
[TBL] [Abstract][Full Text] [Related]
15. Advances in paclitaxel combinations for treating cervical cancer.
Della Corte L; Barra F; Foreste V; Giampaolino P; Evangelisti G; Ferrero S; Bifulco G
Expert Opin Pharmacother; 2020 Apr; 21(6):663-677. PubMed ID: 32037907
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab vs dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent or persistent cervical carcinoma: Japan Clinical Oncology Group Study (JCOG1311).
Ishikawa M; Nakamura K; Shibata T; Tanaka K; Kitagawa R; Kobayashi H; Yaegashi N;
Jpn J Clin Oncol; 2018 Dec; 48(12):1096-1100. PubMed ID: 30295796
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer.
Ilhan Y; Tatli AM; Teker F; Onder AH; Kose F; Geredeli C; Karaagac M; Kaplan MA; Inanc M; Goktas Aydin S; Kargi A; Arak H; Ozturk B; Besen AA; Selvi O; Korkmaz M; Oruc Z; Bozkurt O; Bilici A; Bayram S; Dae SA; Ozdogan M; Coskun HS; Sezgin Goksu S
Int J Gynecol Cancer; 2022 Apr; 32(4):502-507. PubMed ID: 35086927
[TBL] [Abstract][Full Text] [Related]
18. Combination of weekly paclitaxel-carboplatin plus standard bevacizumab as neoadjuvant treatment in stage IB-IIB cervical cancer.
Maene C; Salihi RR; Van Nieuwenhuysen E; Han SN; Concin N; Vergote I
Int J Gynecol Cancer; 2021 Jun; 31(6):824-828. PubMed ID: 33858952
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer.
Shi Y; Chen J; Shi B; Liu A
Gynecol Oncol; 2022 Feb; 164(2):379-385. PubMed ID: 34920886
[TBL] [Abstract][Full Text] [Related]
20. Short-term curative effect and safety of bevacizumab combined with chemotherapy for treating recurrent and metastatic cervical cancer.
Xiao Y; Cheng HJ; Wang L; Luo SX
Eur J Gynaecol Oncol; 2017; 38(1):76-79. PubMed ID: 29767869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
